The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index.
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial
Abstract
Background Calcium antagonists are widely prescribed for angina pectoris but their effect on clinical outcome is controversial. We aimed to investigate the effect of the calcium antagonist nifedipine on long-term outcome in patients with stable angina pectoris.Methods We randomly assigned 3825 patients with treated stable symptomatic coronary disease to double-blind addition of nifedipine GITS (gastrointestinal therapeutic system) 60 mg once daily and 3840 to placebo. The primary endpoint was the combination of death, acute myocardial infarction, refractory angina, new overt heart failure, debilitating stroke, and peripheral revascularisation. Mean follow-up was 4.9 years (SD 1.1). Analysis was by intention to treat.Findings 310 patients allocated nifedipine died (1.64 per 100 patient-years) compared with 291 people allocated placebo (1.53 per 100 patient-years; hazard ratio 1.07 [95% CI 0.91-1.25], p=0.41). Primary endpoint rates were 4.60 per 100 patient-years for nifedipine and 4.75 per 100 patient-years for placebo (0.97 [0.88-1.07], p=0.54). With nifedipine, rate of death and any cardiovascular event or procedure was 9.32 per 100 patient-years versus 10.50 per 100 patient-years for placebo (0.89 [0.83-0.95], p=0.0012). The difference was mainly attributable to a reduction in the need for coronary angiography and interventions in patients assigned nifedipine, despite an increase in peripheral revascularisation. Nifedipine had no effect on the rate of myocardial infarction.Interpretation Addition of nifedipine GITS to conventional treatment of angina pectoris has no effect on major cardiovascular event-free survival. Nifedipine GITS is safe and reduces the need for coronary angiography and interventions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the indication of stable coronary disease, none of these medications have been shown to reduce the risk of mortality or myocardial infarction.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [248]
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Julius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16451-9 · Cited by 2,558
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14286-9 · Cited by 2,142
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Research works printed but not linked: 1
- Lubsen, 1998, Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS, Eur Heart J, 19, I20
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
Authors/Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,829
Self-citation
Metadata
- Authors
- Poole-Wilson, P. A., Lubsen, J., Kirwan, B.-A., van Dalen, F. J., Wagener, G., Danchin, N., Just, H., Fox, K. A., Pocock, S. J., Clayton, T. C., Motro, M., Parker, J. D., Bourassa, M. G., Dart, A. M., Hildebrandt, P., Hjalmarson, Å., Kragten, J. A., Molhoek, G. P., Otterstad, J.-E., Seabra-Gomes, R., Soler-Soler, J., & Weber, S.
- Affiliations
- Imperial College London (GB)
- Erasmus MC (NL)
- State Oil Company of Azerbaijan Republic (Azerbaijan) (AZ)
- Bayer (Germany) (DE)
- Hôpital Européen Georges-Pompidou (FR)
- University of Freiburg (DE)
- University of Edinburgh (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Tel Aviv University (IL)
- Mount Sinai Hospital (CA)
- Montreal Heart Institute (CA)
- The Alfred Hospital (AU)
- Frederiksberg Hospital (DK)
- Sahlgrenska University Hospital (SE)
- Atrium Medisch Centrum Parkstad (NL)
- Medisch Spectrum Twente (NL)
- Sykehuset i Vestfold (NO)
- Hospital de Santa Cruz (PT)
- Université Paris Descartes (FR)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 364
- Issue
- 9437
- Pages
- 849-857
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2121708260
- Cited by
- 511
- References
- 40
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 4 · 2023: 16 · 2022: 10 · 2021: 7 · 2020: 14 · 2019: 14 · 2018: 16 · 2017: 28 · 2016: 21 · 2015: 34 · 2014: 22 · 2013: 24 · 2012: 27
- FWCI
- 31.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Bayer
- Bayer HealthCare
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- nifedipine, stable angina, calcium channel blockers, cardiovascular mortality, cardiovascular morbidity, gastrointestinal therapeutic system, coronary angiography, revascularization, myocardial infarction, heart failure, stroke, event-free survival
- MeSH terms
- Angina Pectoris, Calcium Channel Blockers, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Male, Middle Aged, Nifedipine, Survival Analysis, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(04)16980-8
- The paper
- Poole-Wilson, P. A., Lubsen, J., Kirwan, B.-A., van Dalen, F. J., Wagener, G., Danchin, N., Just, H., Fox, K. A., Pocock, S. J., Clayton, T. C., Motro, M., Parker, J. D., Bourassa, M. G., Dart, A. M., Hildebrandt, P., Hjalmarson, Å., Kragten, J. A., Molhoek, G. P., Otterstad, J.-E., . . . Weber, S. (2004). Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(04)16980-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.